TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01095640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene 0.3% topical gel
Description: once a day, 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: adapalene 0.3% topical gel
Description: once a day, 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adapalene 0.3% topical gel
Description: once a day, 84 days
Study: NCT03255239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair
Description: Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair
Description: Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventral hernia repair
Description: Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
Study: NCT03467321

Intervention type: OTHER
Intervention: Physical characteristic assessment
Description: Physical characteristics related to balance, pulmonary function and low back pain were evaluated

Intervention type: OTHER
Intervention: Physical characteristic assessment
Description: Physical characteristics related to balance, pulmonary function and low back pain were evaluated
Study: NCT01048008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM-CHOC-PEN
Description: DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued.
Study: NCT03473678

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich beetroot juice
Description: concentrated beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: concentrated beetroot juice
Study: NCT00962208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology lenses
Description: Nightly use of orthokeratology to correct the refractive error for a period of two years

Intervention type: DEVICE
Group type: OTHER
Intervention: single-vision spectacle lenses
Description: Daily use of spectacles to correct the refractive error for a period of two years
Study: NCT03491059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 labeled nicotine
Description: Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
Study: NCT01360697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JADE
Description: 1. The nurse will complete the CA using standardized protocol including blood \& urine tests, eye \& feet examination.~2. Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~3. Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications \& healthy lifestyles, perform self blood glucose monitoring as appropriate.~4. At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight \& blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~5. After the FU visit, the patients will see the nurse or HCA again to clarify any issues \& concerns, reinforce compliance \& record any changes in medications.~6. After each FU visit, the HCA will generate summary reports to be given to patients \& doctors to promote sharing of information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-JADE
Description: Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
Study: NCT01898455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RhinoChill intranasal cooling
Description: The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
Study: NCT03726489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Daavlin 7 series 3 panel narrow band phototherapy home units
Description: Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors

Intervention type: DEVICE
Group type: OTHER
Intervention: narrow band phototherapy clinic units
Description: Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
Study: NCT02602769

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome profiling
Description: The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome profiling
Description: The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
Study: NCT03917849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises program for patellar tendinopathy
Description: To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
Study: NCT03046108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blind injection of Triamcinolone
Description: blind injection of 40 mg of triamcinolone (trigon depot ®)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided injection
Description: Introduction of a needle based guided by ultrasound
Study: NCT03046108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided injection
Description: Introduction of a needle based guided by ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound guided injection
Description: Introduction of a needle based guided by ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of mepivacaine
Description: ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of mepivacaine
Description: ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of mepivacaine
Description: ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of Triamcinolone
Description: ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of Triamcinolone
Description: ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: guided injection of Triamcinolone
Description: ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
Study: NCT01853020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
Study: NCT02592291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHealth
Description: The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
Study: NCT02628639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-density electroencephalography
Study: NCT03274167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study: NCT00910104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven®
Description: 10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
Study: NCT02969122

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard gastrectomy with D2 lymphadenectomy
Description: standard distal or total gastrectomy and accorded D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard gastrectomy with D2 lymphadenectomy
Description: standard distal or total gastrectomy and accorded D2 lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyperthermic intraperitoneal chemotherapy
Description: Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperthermic intraperitoneal chemotherapy
Description: Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extensive intraperitoneal lavage
Description: Lavage of peritoneal cavity with 1000ml saline for 10 times

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive intraperitoneal lavage
Description: Lavage of peritoneal cavity with 1000ml saline for 10 times

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative chemotherapy
Description: Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chemotherapy
Description: SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Description: SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
Study: NCT02542657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT02777138

Intervention type: OTHER
Intervention: Maintaining a normal daily living lifestyle
Description: participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
Study: NCT02407808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC
Description: Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
Study: NCT02407808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Study: NCT02140281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (cefadroxil alone)
Description: A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (cefadroxil alone)
Description: A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD1722 followed by cefadroxil
Description: 15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B - AZD1722 followed by cefadroxil
Description: 15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
Study: NCT02610166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game
Description: In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Children in usual care group receive standard medical care.
Study: NCT03866291

Intervention type: OTHER
Intervention: No intervention, observational
Description: See above

Intervention type: OTHER
Intervention: No intervention, observational
Description: See above
Study: NCT04694209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillary and mandibular telescopic retained overdentures supported by 4 implants
Description: The wax of the trial denture was converted into heat-cured acrylic resin using conventional packing and flasking techniques. The prosthesis was finished, polished and screwed in the patient's mouth. Engaging (Internal hex) cylindrical, plastic patterns (Octa plastic cylinder, multi unit abutment, Red, Dentis, Daegu -Korea) were used to construct the primary copings of the telescopic prosthesis.The finished primary copings were scanned using a lab scanner (Shera Echo-scan 7. Dental Wings, Montreal-Canada). This was necessary to design and to mill the wax pattern of the secondary copings using CAD/CAM technology (Dental Wings Software, Dental Wings, Montreal -Canada). Secondary coping was designed to properly fit to the primary coping. The framework was then tried in. At that time it was ready for its intra-oral luting to the secondary copings.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary and mandibular screw retained hybrid prostheses supported by 4 implants
Description: Framework of the hybrid prosthesis is waxed using plastic copings attached to multiunit abutments. once the framework is finished , bite is recorded, teeth are set up and the waxed up prosthesis are tried in. IF accepted the wax is eliminated the wax up denture is converted inti heat cured acrylic resin
Study: NCT02407808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
Study: NCT03122639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study: NCT01474525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Glucose Telemonitoring System
Description: The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home Blood Glucose Telemonitoring System
Description: The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers.
Study: NCT03536013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other: Full-thickness placental allograft
Description: A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
Study: NCT03647930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microporous Polysaccharide Hemospheres (MPH)
Description: Microporous Polysaccharide Hemospheres (MPH)
Study: NCT02570984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: anti-ige injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator arm, injection similar to active
Study: NCT00659802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 low dose
Description: HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching dose of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004 high dose
Description: HMPL-004, 600 mg (3 x 200 mg) t.i.d. (total of 1800 mg/day).
Study: NCT03608319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250
Description: 9.6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250
Description: 9.6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250
Description: 9.6 mg
Study: NCT03519269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navio™ Robotics-assisted Surgical System
Description: Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
Study: NCT04180397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide 10 mg/ml for injection/infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline used as placebo (injection/infusion)
Study: NCT04375761

Intervention type: PROCEDURE
Intervention: Collection of Biological Samples
Description: Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.

Intervention type: PROCEDURE
Intervention: Symptom and Exposure Surveys
Description: Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.
Study: NCT04379362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal laser ablation
Description: Focal laser ablation
Study: NCT04370548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARE-BV1clindamycin phosphate vaginal gel, 2%
Description: One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DARE-BV1clindamycin phosphate vaginal gel, 2%
Description: One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
Study: NCT02466750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Western Equine Encephalitis (WEE) Vaccine
Description: Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92